SHIM
CTKB icon

Stone House Investment Management’s Cytek Biosciences CTKB Stock Holding History

Stone House Investment Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.39K Buy
+318
New +$1.5K ﹤0.01% 653

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stone House Investment Management's CTKB Position: Q1 2026 in Review

Stone House Investment Management opened a new position in Cytek Biosciences (CTKB) in Q1 2026: 318 shares worth $1.39K. The stake represents ﹤0.01% of the portfolio and ranks #653 among its holdings.

165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Stone House Investment Management held 318 shares of Cytek Biosciences worth $1.39K as of Q1 2026.
  • Cytek Biosciences was a new Stone House Investment Management position in Q1 2026.
  • Cytek Biosciences made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #653 holding.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.